Polymers Including Active Agents

• US 20190151452A1
• Filed: 01/17/2019
• Published: 05/23/2019
• Est. Priority Date: 04/29/2014
• Status: Active Grant

• Current Assignee: Microvention Incorporated (Terumo Corporation)
• Original Assignee: Microvention Incorporated (Terumo Corporation)
• Inventors: Cruise, Gregory M., Harris, Clayton G., Constant, Michael J.
• Granted Patent: US 10,946,100 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 31/7068 having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• CPC Class Codes: A61K 31/787 containing heterocyclic rings having nitrogen as a ring hetero atom
• CPC Class Codes: A61K 47/32 Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers , poly(meth)acrylates, or polyvinyl pyrrolidone
• CPC Class Codes: A61K 47/58 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
• CPC Class Codes: A61K 49/04 X-ray contrast preparations
• CPC Class Codes: A61K 9/0092 Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
• CPC Class Codes: A61L 2430/36 for embolization or occlusion, e.g. vaso-occlusive compositions or devices artificial blood vessels A61L27/507
• CPC Class Codes: A61L 31/145 Hydrogels or hydrocolloids
• CPC Class Codes: A61L 31/148 Materials at least partially resorbable by the body
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61L 31/18 Materials at least partially X-ray or laser opaque
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07F 15/0093 without a metal-carbon linkage
• CPC Class Codes: C07H 19/06 Pyrimidine radicals

Abstract

Polymers are described herein comprising: a reaction product of a prepolymer solution including at least one macromer and at least one visualization agent; and an active agent electrostatically bound to the polymer filament or chemically bound to the at least one monomer; wherein the polymer filament does not include metallic support members.

Claims

1. A method of forming a therapeutic polymer filament comprising:

reacting a prepolymer solution including at least one macromer, at least one visualization agent, and an active agent electrostatically bound to the polymer filament or chemically bound to the at least one monomer to form the therapeutic polymer filament.

2. The method of claim 1, further comprising adding the at least one monomer to the prepolymer solution, wherein the at least one monomer is t-butyl acrylamide, 2-hydroxyethyl methacrylate, hydroxyl propyl acrylate, hydroxyl butylacrylate, or a combination thereof.

3. The method of claim 1, wherein the at least one monomer has a concentration of between about 5% and about 40% w/w of the prepolymer solution.

4. The method of claim 1, wherein the at least one macromer is poly(ethylene glycol), poly(propylene glycol), poly(tetramethylene oxide), ethoxylated pentaerythritol, ethoxylated trimethylolpropane, poly(vinyl alcohol), or a combination thereof.

5. The method of claim 1, wherein the at least one macromer has a concentration of between about 15% and about 25% w/w of the prepolymer solution or has a molecular weight of between about 100 g/mole and about 5,000 g/mole.

6. The method of claim 1, further comprising adding the at least one crosslinker to the prepolymer solution, wherein the at least one crosslinker includes an ester, a carbonate, a thioester, or a combination thereof.

7. The method of claim 1, wherein the at least one visualization agent is barium, bismuth, tantalum, platinum, gold, iodine-containing molecules, barium sulfate, or a combination thereof.

8. The method of claim 1, wherein the active agent is entrapped within the polymer filament or loaded into the polymer filament.

9. The method of claim 1, wherein the active agent is chemically bound to the at least one monomer.

10. A polymerizable pharmaceutical agent having a structure

11. The polymerizable pharmaceutical agent of claim 10, wherein R¹ is

12. The polymerizable pharmaceutical agent of claim 10, wherein R¹ is

13. The polymerizable pharmaceutical agent of claim 10, wherein R¹ is

14. The polymerizable pharmaceutical agent of claim 10, wherein R¹ is

15. The polymerizable pharmaceutical agent of claim 10, wherein R¹ is

16. The polymerizable pharmaceutical agent of claim 10 having a structure

17. The polymerizable pharmaceutical agent of claim 10 having a structure

18. The polymerizable pharmaceutical agent of claim 10 having a structure